Europe Bone Degeneration Therapeutics market size is valued at USD xx million in 2021 and is expected to grow at a prominent growth rate 3.8% during the forecast period 2022 to 2028. The European market provides a detailed overview of the Europe Bone Degeneration Therapeutics market, and that can be segmented by drug type, by route of administration, and by application. By drug type, The Europe Bone Degeneration Therapeutics market has been segmented into Hyaluronic acid, Platelet-rich plasma, Steroids, and cortisone, among Others. The Platelet – Rich Plasma segment is likely to be the largest and fastest-growing segment in terms of drug type. The supremacy of this segment is owing to the application of platelet-rich plasma therapy in bone degeneration disease. It was found that platelet-rich plasma therapy for curing knee osteoarthritis has a high success rate and the efficiency depends on the brutality of knee osteoarthritis. However, Cortisone or steroids is projected to grow with the fastest CAGR during the forecast period. It is mainly because corticosteroid injections can cure various spinal conditions and skeletal, and muscular. Dexamethasone, prednisone, methylprednisolone, and hydrocortisone are FDA-approved corticosteroid injections utilized to decrease inflammation and pain. Such characteristics of corticosteroid injections and their need for numerous bone diseases and injuries fuel the growth of the Bone Degeneration Therapeutics Market Share. Based on the Route of administration, the Europe Bone Degeneration Therapeutics market is segmented into Oral, Parenteral. Among these, the Parenteral segment is expected to have a significant growing market during the forecast period 2022-2028. Based on the Application, the Europe Bone Degeneration Therapeutics market is segmented into Osteopenia, Osteoarthritis, and Spinal Fusion. The Osteoarthritis segment accounts for the largest share in 2021. Based on the distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Homecare Settings. The Hospital Pharmacies segment accounts for the largest share in 2021.
In August 2021, CTI Biopharma Corporation and DRI Healthcare Trust announced the funding of pacrinitib sales and subsequent product approval by the US Food and Drug Administration (FDA).
In October 2019, Amgen acquired Teneobio, Inc